Email this article A Modified Method for Increasing Radiochemical Purity of I-125 for Radiopharmaceuticals
Abstract
Iodine-125 (125I) is one of the radioisotopes widely used in radiopharmaceuticals for diagnosis and therapy of various cancers. Recent reports indicate that there has been shortages in the world supply of this radioiodine isotope. One of the absolute requirements good radiopharmaceuticals must meet is radiochemical purity, which generally has to be above 95 %, with an efficiency of over 90 %. The previous investigation shows that the radiochemical purity is low and does not meet the radiochemical requirement. In this work, we aim at improving the previous method by modifying the Jones reductor-based method. The modified method includes reduction and uniformization of Zn particle sizes, Zn particle compaction, and the performance of reduction process in a closed process flow. The Jones reductor converted impurities into products; in this case, iodate (IO3-) and periodate (IO4-) impurities were converted into iodide (I-), so that 125I product fulfills the radiochemical purity requirements and yielded high efficiency. In this investigation, the 125I previous product was, for the first time, improved with a radiochemical purity of 99.24 % and an efficiency of 97.98 %.
Keywords
Full Text:
PDFReferences
Maiyesni, Mujinah, Witarti et al., Jurnal Kimia Valensi 3 (2013) 65. (in Indonesian)
Maiyesni, Mujinah, D Kurniasih et al., Indonesian Journal of Nuclear Science and Technology 17 (2016) 59. (in Indonesian)
A. Kar, Novel 125I Production and Recovery System, M. Sc. Thesis, Texas A&M University (2007).
A. Tshiband, L. Mputu, R. Tozin et al., J. Biomed. Eng. Med. Devices 01 (2016) 1.
Q. Li, Y. Tian, D. Yang et al., Technol. Cancer Res. Treat. 18 (2019) 1.
R. Li, Z. Ying, Y. Yuan et al., Brachytherapy 18 (2019) 87.
J. Zhou, L. Hao, Z. Shi et al., Oncol. Lett. 14 (2017) 6403.
A. Wals, J. Nanopart. Res. 19 (2017) 152.
M. S. M. Enferadi and A. Shirazi, J. Cancer Res. Ther. 6 (2010) 239.
M. A. Mourad, H. Abd El-Aziz, A. M. Amin et al., Arab J. Nucl. Sci. Appl. 51 (2018) 107.
I. T. Al-Alawi and R.S. Mohammed, Int. Lett. Chem. Phys. Astron. 63 (2016) 90.
C. Maioli, G. Lucignani, A. Strinchini, L. Tagliabue et al., Acta Biomed. 88 (2017) 49.
P. Zhao, M. Q. Zhang, Y. L. Zhang et al., J. Balk. Union Oncol. 22 (2016) 265.
O. L. Da Costa, D. C. B. Souza, A. Feher et al., Brazilian Demand For Iodine - 125 Seeds In Cancer Treatment After A Decade Of Medical Procedure, Proceedings of the International Nuclear Atlantic Conference (INAC) (2017) 1.
C. J. Shen, I. I. Minn, R. F. Hobbs et al., Theranostics 10 (2020) 2888.
A. A. Amin, N. S. Farrag and A. AbdEl-Bary, Br. J. Pharm. Res. 4 (2014) 1873.
A. P. Kiess, I. I. Minn, Y. Chen et al., J. Nucl. Med. 56 (2015) 1401.
L. P. Vincenti, A. Samuel and F. Zarb, Int. J. Radiol. Imaging Technol. 2 (2016) 2.
E. De Bois, R. M. S. De Zanger, H. S. Chan et al., EJNMMI Radiopharm. Chem. 4 (2019) 1.
H. H. Coenen, A. D. Gee, M. Adam et al., J. Label. Compd. Radiopharm. 61 (2018) 402.
C. R. Bush, J. E. Coughlin, T. J. Herold et al., Nucl. Med. Biol. 24 (1997) 479.
M. Vahabzadeh and M. Balali-Mood, Int. J. Occup. Environ. Med. 7 (2016) 116.
B.-J. Ye, B. -G. Kim, M. -J. Jeon et al., Ann. Occup. Environ. Med. 28 (2016) 1.
H. Sadeghpour, M. Alavi, M. Shahedi et al., Trends Radiopharm. Sci. 1 (2015) 15.
M. R. Ghahramani, A. A. Garibov and T. N. Agayev, J. Chromatogr. Sep. Tech. 06 (2014) 1.
R. De Zanger, E. De Blois and W. Breeman, J. Nucl. Med. 58 (2017) 258.
H. Ullah, I. Ahmad, M. Khattak et al., Iran. J. Nucl. Med. 27 (2019) 19.
S. Mushtaq, Y. R. Nam, J. A. Kang et al., ACS Omega 3 (2018) 6903.
J. I. M. van Uhm, G. W. M. Visser, M. J. van der Schans et al., EJNMMI Research 5 (2015) 5.
DOI: https://doi.org/10.55981/aij.2023.1243
Copyright (c) 2023 Atom Indonesia
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
